Speakers
Alejandro Rangel
Associate Professor of Medicine
Universidad Panamericana
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
9:30 am | Panel Discussion: Comprehensively Analyzing the Impact of Aducanumab’s Approval for Alzheimer’s on the Regulatory Landscape for Neurodegenerative Disease
Andrea Crotti
Principal Scientist - Early Discovery
Takeda
Beth Hoffman
Founder, President & Chief Executive Officer
Origami Therapeutics
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
8:30 am | Exploring CNS Application of Protein Degraders to Determine Whether They Can be Utilized in a Selective Manner to Minimize Side Effects & Maximize Therapeutic Outcome
Chris Winrow
Vice President & Head of Translational Medicine
Cyclerion
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
9:30 am | Panel Discussion: Comprehensively Analyzing the Impact of Aducanumab’s Approval for Alzheimer’s on the Regulatory Landscape for Neurodegenerative Disease
Track B - Day 1
2:00 pm | From Concept to Clinic: Targeting the Nitric Oxide-Soluble Guanylate Cyclase-cGMP Pathway for Neurodegenerative Diseases
Daniel Alkon
President –Research
Synaptogenix
Track B - Day 1
1:30 pm | Uncovering Bryostatin Targets Restoration of Synaptic Wiring Lost in Alzheimer’s Degeneration
David Bearss
Chief Scientific, Officer
Halia Therapeutics
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
9:00 am | Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s
Dimitry Ofengeim
Head of Precision Neurology & Neuroinflammation
Sanofi
Pre-Conference Discussion Day
Monday, March 28, 2022
8:02 am | Defining Approaches for Precision Neurology
George Tetz
Chief Executive Officer
CLS Therapeutics & The Human Microbiology Institute
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
9:00 am | Weaponizing the Microbiome Against Alzheimer’s Disease
Gergely Toth
Chief Executive Officer & Chief Scientific Officer
Cantabio
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
11:00 am | Deep Diving into Therapeutic Targeting of the DJ-1 Protein for the Treatment of Parkinson’s Disease
Graham Dempsey
Chief Scientific, Officer
Q-State Bio
Pre-Conference Discussion Day
Monday, March 28, 2022
1:03 pm | Investigating Therapeutic Discovery Platforms for Oligonucleotides Targeting Neurodegenerative Diseases
Habib Baghirov
Senior Scientific, Business Analyst
Roche
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
9:30 am | Panel Discussion: Comprehensively Analyzing the Impact of Aducanumab’s Approval for Alzheimer’s on the Regulatory Landscape for Neurodegenerative Disease
Pre-Conference Discussion Day
Monday, March 28, 2022
8:03 am | Utilizing Innovative Delivery Technology to Move Across the Blood Brain Barrier & Optimize Precision Targeting of Neurons
Jamil Beg
Life Science, Venture Capitalist, & Entrepreneur
5am Ventures
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks
Je Min Yoo
Chief Technology, Officer
Biographene
Track A - Day 1
2:00 pm | The New Target Journey: How to Progress from Target Identification & Illustrate Meaningful Effect in Pre-Clinical Models
Johannes Krupp
Research Program Director for Neurology
Servier
Pre-Conference Discussion Day
Monday, March 28, 2022
1:02 pm | Exploring RNA Targeted Approaches for Rare Movement Disorders
John Gustofson
Managing Director
AbbVie
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks
John Hey
Chief Scientific Officer
Alzheon
Track B - Day 2
2:30 pm | Fluid & Imaging Biomarkers in ALZ-801 Development: A First-in-Class Oral Disease Modifying Agent for Alzheimer’s Disease
Jonathan Behr
Partner
Dementia Discovery Fund
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks
Jonathan Proto
Principal Scientist
Sanofi
Track A - Day 1
1:30 pm | Learning How to Integrate Information on Cellular Communication & Pathways for a Multi-Omic Approach to Target Identification
Judy Walker
Chief Medical, Officer
Cerecin
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
9:30 am | Metabolic Dysfunction in Neurodegenerative Disorders: Spotlight on Parkinson’s, Huntington’s & Alzheimer’s
Katherine Deng
Principal Scientist
AbbVie
Track A - Day 2
1:30 pm | In Vitro Transcytosis Models for BBB targeting CNS Drug Screening
Keechan Ahn
Chief Scientific Officer
Astrogen
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
11:30 am | Introducing a Novel Drug Assessment Through Brain Microdialysis Examining BBB Permeability
Lisa Shafer
Chief Scientific Officer
Cerebral Therapeutics
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
11:00 am | Analyzing Translational Approaches for Brain Targeted Drug Delivery
Magdalene Moran
President & Chief Scientific Officer
Carraway Therapeutics
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
11:30 am | Enhancing Lysosomal Function as a Therapeutic Strategy for Parkinson’s Disease
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
9:30 am | Panel Discussion: Comprehensively Analyzing the Impact of Aducanumab’s Approval for Alzheimer’s on the Regulatory Landscape for Neurodegenerative Disease
Manuel Sanchez-Felix
Senior Fellow, Novel Delivery Technologies
Novartis
Track B - Day 1
12:32 pm | Analyzing Key Clinical Trial Updates
Marcy Taylor
Vice President of Research
Treventis
Track A - Day 2
1:00 pm | Discovery of Small Molecule Dual Inhibitors of Abeta & Tau Aggregation Using CCM Technology
Martin Tolar
Founder, President & Chief Executive Officer
Alzheon
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
3:30 pm | ALZ-801 Phase 3 Program: Lessons & The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease
Melissa Geddie
Principal Scientist – Antibody Discovery
Biogen
Track A - Day 1
12:32 pm | Streamlining Target Discovery
Michela Gallagher
Founder & Chief Executive Officer
Agene Bio
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
4:00 pm | HOPE4MCI - Exploring Hippocampal Overactivity Prevention in the Elderly
Michele Vendruscolo
Professor
University of Cambridge
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
8:30 am | Targeting Abeta Oligomer Formation Using Small Molecules
Murali Gopalakrishnan
Global Head of Neuroscience Search & Evaluation
AbbVie
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
8:25 am | Chair’s Opening Remarks
Day Two
Wednesday, March 30, 2022
Wednesday, March 30, 2022
8:25 am | Chair’s Opening Remarks
Phllip Kong
Associate Director for Translational Medicine
Alector
Track A - Day 2
12:03 pm | Closing the Translational Gap: Update on Neurodegenerative Disease Models & Imaging
Raj Ganesan
Senior Director -Protein Engineering & Antibody Discovery Research
Alector
Track B - Day 1
2:30 pm | Versatile Therapeutic Intervention Approaches to Modulate Microglial Activity for the Treatment of Neurodegenerative Disease
Raphael Lis
Assistant Professor in Regenerative & Reproductive Medicine & Director of the Starr Foundation Stem Cell Derivation Laboratory
Weill Cornell Medicine
Track A - Day 2
2:30 pm | Exploring the Generation of Vascularised & Perfusable Brain Organoid for Disease Modelling
Rob Shaffer
Founder
Enable Therapeutics
Pre-Conference Discussion Day
Monday, March 28, 2022
1:03 pm | Targeting Glycogen in Childhood Dementia with Expansion Potential to Larger Neurodegenerative Indications
Ross Jeggo
Global Head of Neuroscience & Immuno-Inflammation Therapeutic Aria
Servier
Day One
Tuesday, March 29, 2022
Tuesday, March 29, 2022
12:00 pm | Showcasing LRRK2 Inhibitors as Treatment for Parkinson’s Disease
Sharon Rosenzweig-Lipson
Vice President of Research & Development
AgeneBio
Stan Chamberlain
Chief Scientific Officer
T3D Therapeutics